Why the study?
Is long-term use of low-molecular-weight heparin (enoxaparin) safe and effective for anticoagulation in hemodialysis patients?
Is long-term use of low-molecular-weight heparin (enoxaparin) safe and effective for anticoagulation in hemodialysis patients?
Long-term use of low-molecular-weight heparin (enoxaparin) at a reduced dose is practical and safe for hemodialysis patients.
Answers are grounded in this paper and cite their sources.
May allow reduced-dose enoxaparin in long-term HD without adverse platelet or lipid effects; extends observational data but leaves open RCT confirmation.
BACKGROUND: Low-molecular-weight-heparin (LMWH) is not routinely used as anticoagulant in hemodialysis (HD). The ideal dose and the safety of long-term use are not known. METHODS: A prospective three-phase interventional study. Phase 1 involved dose titration, phase 2 safety and efficacy and phase 3 routine practice. RESULTS: During 7 years of the use of the LMWH enoxaparin (EN), 236 patients were treated with a total number of 60,987 HD sessions. The mean dose used during the titration phase was 0.43 +/- 0.16 mg/kg/session, which was subsequently reduced in phase 3 to 0.36 +/- 0.14 mg/kg/session. The long-term effects of EN on the platelet count and lipid profile were comparable to unfractionated heparin. CONCLUSION: The long-term use of LMWH (EN) with a reduced dose in HD is practical and safe.
No takes yet. Share an insight, caveat, or question.
Bernieh et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: